These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 27250932)

  • 1. Nonclinical Evaluations of Small-Molecule Oncology Drugs: Integration into Clinical Dose Optimization and Toxicity Management.
    Dambach DM; Simpson NE; Jones TW; Brennan RJ; Pazdur R; Palmby TR
    Clin Cancer Res; 2016 Jun; 22(11):2618-22. PubMed ID: 27250932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose Finding of Small-Molecule Oncology Drugs: Optimization throughout the Development Life Cycle.
    Jänne PA; Kim G; Shaw AT; Sridhara R; Pazdur R; McKee AE
    Clin Cancer Res; 2016 Jun; 22(11):2613-7. PubMed ID: 27250931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lessons Learned: Dose Selection of Small Molecule-Targeted Oncology Drugs.
    Bullock JM; Rahman A; Liu Q
    Clin Cancer Res; 2016 Jun; 22(11):2630-8. PubMed ID: 27250934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rendering the 3 + 3 Design to Rest: More Efficient Approaches to Oncology Dose-Finding Trials in the Era of Targeted Therapy.
    Nie L; Rubin EH; Mehrotra N; Pinheiro J; Fernandes LL; Roy A; Bailey S; de Alwis DP
    Clin Cancer Res; 2016 Jun; 22(11):2623-9. PubMed ID: 27250933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety Profile Based on Concordance of Nonclinical Toxicity and Clinical Adverse Drug Reactions for Blood Cancer Drugs Approved in Japan.
    Kubota S; Saito K; Ono S; Kodama Y
    Drugs R D; 2017 Mar; 17(1):133-143. PubMed ID: 27995532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Found in Translation: Maximizing the Clinical Relevance of Nonclinical Oncology Studies.
    Spilker ME; Chen X; Visswanathan R; Vage C; Yamazaki S; Li G; Lucas J; Bradshaw-Pierce EL; Vicini P
    Clin Cancer Res; 2017 Feb; 23(4):1080-1090. PubMed ID: 27551002
    [No Abstract]   [Full Text] [Related]  

  • 7. Regulatory Approaches to Nonclinical Reproductive Toxicity Testing of Anti-Cancer Drugs.
    Barrow P; Schmitt G
    Anticancer Agents Med Chem; 2017; 17(9):1171-1183. PubMed ID: 27297974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinically Relevant Concentrations of Anticancer Drugs: A Guide for Nonclinical Studies.
    Liston DR; Davis M
    Clin Cancer Res; 2017 Jul; 23(14):3489-3498. PubMed ID: 28364015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor inhibition strategies in oncology.
    Harari PM
    Endocr Relat Cancer; 2004 Dec; 11(4):689-708. PubMed ID: 15613446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategy for the development of novel anticancer drugs.
    Saijo N; Tamura T; Nishio K
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S97-101. PubMed ID: 12856152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translational modeling and simulation approaches for molecularly targeted small molecule anticancer agents from bench to bedside.
    Yamazaki S; Spilker ME; Vicini P
    Expert Opin Drug Metab Toxicol; 2016; 12(3):253-65. PubMed ID: 26799750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety Pharmacology of Anticancer Agents.
    Martin PL
    Handb Exp Pharmacol; 2015; 229():405-31. PubMed ID: 26091649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potentials and limitations of nonclinical safety assessment for predicting clinical adverse drug reactions: correlation analysis of 142 approved drugs in Japan.
    Tamaki C; Nagayama T; Hashiba M; Fujiyoshi M; Hizue M; Kodaira H; Nishida M; Suzuki K; Takashima Y; Ogino Y; Yasugi D; Yoneta Y; Hisada S; Ohkura T; Nakamura K
    J Toxicol Sci; 2013; 38(4):581-98. PubMed ID: 23824014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting toxicities in humans by nonclinical safety testing: an update with particular reference to anticancer compounds.
    Ahuja V; Bokan S; Sharma S
    Drug Discov Today; 2017 Jan; 22(1):127-132. PubMed ID: 27644594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extrapolation of Oligonucleotide Dose Levels Used in Nonclinical Toxicity Studies to Selection of Safe Starting Dose Levels in Human Clinical Trials.
    Kornbrust D
    Nucleic Acid Ther; 2019 Jun; 29(3):123-125. PubMed ID: 30817231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology.
    McDermott U; Settleman J
    J Clin Oncol; 2009 Nov; 27(33):5650-9. PubMed ID: 19858389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety assessment considerations and strategies for targeted small molecule cancer therapeutics in drug discovery.
    Westhouse RA
    Toxicol Pathol; 2010 Jan; 38(1):165-8. PubMed ID: 19907054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.
    Roberts SA; Andrews PA; Blanset D; Flagella KM; Gorovits B; Lynch CM; Martin PL; Kramer-Stickland K; Thibault S; Warner G
    Regul Toxicol Pharmacol; 2013 Dec; 67(3):382-91. PubMed ID: 24012707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety Lead Optimization and Candidate Identification: Integrating New Technologies into Decision-Making.
    Dambach DM; Misner D; Brock M; Fullerton A; Proctor W; Maher J; Lee D; Ford K; Diaz D
    Chem Res Toxicol; 2016 Apr; 29(4):452-72. PubMed ID: 26625186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.